Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 2,214 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Terminated Phase 4 Interventional

KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections

NCT00132951
View directory record Official record
Conditions
Respiratory Tract Infections, Chronic Bronchitis, Pneumonia
Interventions
Telithromycin, Azithromycin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 35 Years
Enrollment
2,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2009 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Safety Study of BIIB033 in Subjects With Multiple Sclerosis

NCT01244139
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Interventions
BIIB033, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma

NCT03015610
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux
Interventions
commercially available lansoprazole, matched placebo
Drug
Lead sponsor
Jason Lang, M.D., M.P.H.
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

NCT04188379
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
efgartigimod, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
9
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 24, 2026, 10:29 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Urogynecologic Surgery

NCT02287246
View directory record Official record
Conditions
Postoperative Pain
Interventions
Extended-Release liposomal bupivacaine (Exparel), Normal saline
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy

NCT04620369
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Nasal Vestibulitis
Interventions
Placebo Administration, Questionnaire Administration, Rose Geranium in Sesame Oil Nasal Spray
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Vericiguat on Peripheral Vascular Function, Patient Health Status and Inflammation

NCT05420012
View directory record Official record
Conditions
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Interventions
Vericiguat, Placebo
Drug
Lead sponsor
Josef Stehlik
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 24, 2026, 10:29 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

NCT01656252
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

NCT03299686
View directory record Official record
Conditions
Asthma
Interventions
CJM112, Placebo to CJM112
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Fullerton, California • Riverside, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

NCT03918629
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
1,994 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
52
States / cities
Athens, Alabama • Huntsville, Alabama • Chandler, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Double Blinded Randomized Trial Between Lidocaine And Plain Gel For Urethral Straight Catheterization And The Q-Tip Test

NCT00883103
View directory record Official record
Conditions
Pain
Interventions
2% Lidocaine jelly, Plain aqueous gel
Drug
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Study Investigating the Effects of a Novel Weight Management Program

NCT01875354
View directory record Official record
Conditions
Overweight
Interventions
Dietary Supplements and TR90 Eating Plan, Placebo and Low Fat Eating Plan
Dietary Supplement
Lead sponsor
Pharmanex
Industry
Eligibility
18 Years to 65 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Logan, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury

NCT00755079
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
extended release beta-2 adrenergic agonist, placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours

NCT01221246
View directory record Official record
Conditions
Stroke
Interventions
GM602, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Pasadena, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 24, 2026, 10:29 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SARS Coronavirus Vaccine (SARS-CoV)

NCT00533741
View directory record Official record
Conditions
Coronavirus (SARS-CoV)
Interventions
Aluminum hydroxide, Placebo, SARS-CoV
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

NCT05098938
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 24, 2026, 10:29 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

BPL-1357 Against H1N1 Influenza Virus Challenge

NCT07215858
View directory record Official record
Conditions
Influenza, Human
Interventions
BPL-1357 IM, BPL-1357 IN, Placebo IM, Placebo IN
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 24, 2026, 10:29 PM EDT
Terminated Phase 2 Interventional

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT07037420
View directory record Official record
Conditions
Acromegaly
Interventions
ALXN2420, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Torrance, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 4 Interventional Results available

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03573323
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Ixekizumab, Guselkumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis

NCT01358240
View directory record Official record
Conditions
Tinea Pedis, Athlete's Foot
Interventions
Econazole Nitrate Foam 1%, Vehicle Foam, Econazole Nitrate Cream 1%, Placebo Cream
Drug · Other
Lead sponsor
AmDerma
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Fremont, California • Hockessin, Delaware • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 3 Interventional Results available

Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis

NCT01132118
View directory record Official record
Conditions
Rheumatoid Arthritis, Insulin Resistance
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 24, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease

NCT03004638
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
MEDI6012 40 mg, Placebo, MEDI6012 120 mg, MEDI6012 300 mg, Placebo IV Push, MEDI6012 IV Push
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
60 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Anniston, Alabama • Jacksonville, Florida • Port Orange, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 24, 2026, 10:29 PM EDT